- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tarrytown Today
By the People, for the People
Nordea Investment Management AB Boosts Regeneron Pharmaceuticals Stake
Nordea Investment Management AB increased its holdings in Regeneron Pharmaceuticals by 118.1% in the fourth quarter.
Mar. 23, 2026 at 9:48am
Got story updates? Submit your updates here. ›
Nordea Investment Management AB, an investment management firm, boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 118.1% during the fourth quarter, according to the company's recent filing with the Securities & Exchange Commission. The fund now owns 137,321 shares of the biopharmaceutical company's stock, worth approximately $105.8 million.
Why it matters
Regeneron Pharmaceuticals is a prominent biopharmaceutical company known for its innovative drug discovery and development. The increase in Nordea's stake suggests the investment firm sees strong potential in Regeneron's future growth and performance.
The details
Nordea Investment Management AB acquired an additional 74,350 shares of Regeneron Pharmaceuticals during the fourth quarter, bringing its total holdings to 137,321 shares. This represents approximately 0.13% of Regeneron's outstanding shares.
- Nordea Investment Management AB boosted its stake in Regeneron Pharmaceuticals during the fourth quarter of 2025.
The players
Nordea Investment Management AB
An investment management firm that has increased its stake in Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals, Inc.
A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.
The takeaway
Nordea's increased investment in Regeneron Pharmaceuticals reflects the firm's confidence in the biopharmaceutical company's growth potential and ability to develop innovative treatments for serious medical conditions.
